Brief: Inhibitors

Brief: Inhibitors

Brief: Inhibitors

Brief: Inhibitors

Brief: Inhibitors

Brief: Themitochondrionis a double-membrane-bounddiscrete organellefound in mosteukaryoticorganisms, generating most of the cell's supply ofadenosine triphosphate(ATP) and controlling the cellular basal metabolic rate, called as the cell's powerhouses. In addition to supplying cellular energy, mitochondria are the major source of ROS (reactive oxygen species) that reflect the level of cellular oxidative stress and play an important role in mitochondria ROS signaling such as apoptosis, proliferation, and aging, etc. In addition, the fine modulation of mitochondrial calcium (Ca2+) homeostasis plays a fundamental role in many of the processes involving this organelle. Mitochondrial Ca2+accumulation is a tightly controlled process, in turn regulating functions as diverse asaerobic metabolismand induction ofcell death. Mitochondrial DNA mutations may lead to many mitochondrial metabolic disorders, and are thought to contribute to aging by promoting apoptosis. Mitochondria therefore represent an attractive drug target for metabolic diseases, neurodegeneration, or hyperproliferative diseases (cancer).A number of pre-clinical and clinical data have shown that mitochondria as drug targets have great potential. Small molecule drugs or biologics can act on mitochondria through various pathways including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca2+modulation, and control of oxidative stressviadecrease or increase of mitochondrial ROS accumulation. Mitochondrial Targeting Compound Library from SAB, a unique collection of 64 compounds targeting mitochondria, can be used for research in mitochondrial medicine and related target study

Brief: Bioactive lipids have been shown to provide health benefits either through modification of tissue fatty acid composition or induction of cell signaling pathways, due to their pivotal role in immune regulation, inflammation, and maintenance of tissue homeostasis. While some health benefits are derived from consumption of short to medium-chain fatty acids, evidence suggests that the polyunsaturated fatty acids (PUFAs) are the most important bioactive lipids. PUFAs are found mostly in plant seed oils and are important substrates for the biosynthesis of cellular hormones (eicosanoids) and other signaling compounds that modulate human health. The beneficial health effects of PUFAs seem to be dependent on their isomer configuration as the cis-isomer is the predominant bioactive form which enhances membrane fluidity when incorporated into cells. Increased membrane fluidity enhances cell to cell communication and helps maintain normal homeostasis or prevent the development of metabolic disorders. The SABs?Bioactive Lipid Compound Library, a unique collection of 213 bioactive lipids related compounds including agonists and antagonists targeting paracrine and autocrine signaling, can be used for research in bioactive lipids, and high throughput screening (HTS) and high content screening (HCS).

Brief:

Brief: Apoptosisis a form ofprogrammed cell deaththat occurs inmulticellular organisms. In contrast tonecrosis, which is a form of traumatic cell death that results from acute cellular injury, apoptosis is a highly regulated and controlled process that confers advantages during an organism's lifecycle. Apoptosis leads to characteristic cell changes (morphology): the cell breaks apart into multiple vesicles calledapoptotic bodies, which undergo phagocytosis. Apoptosis is regulated by both pro-apoptotic (such as Fas receptor and caspases) and anti-apoptotic (such as Bcl-2 and IAP) factors. Disordered apoptosis is implicated in a variety of human diseases. Inhibition ofapoptosiscan result in a number of cancers, autoimmunediseases, inflammatory diseases, and viral infections.Excessive apoptosis may also be a feature of some conditions such as autoimmune diseases, neurodegenerative diseases, and ischemia-associated injury.Consequently, considerable interest has arisen in therapeutic strategies for cancer, autoimmune diseases, and neurodegenerative diseases by modulating apoptosis pharmacologically. SABs collection of 191 apoptosis-related compounds, Apoptosis Compound Library, is divided accordingly with compounds designed for either pro- or anti-apoptosis purposes and can be used for research in cancer and neurodegenerative diseases.

Brief: Hematologic diseases (hematonosis), disorders of the blood and blood-forming organs, afflict millions of Americans. In addition to hematological malignancies, such as leukemia and lymphomas, children and adolescents can suffer blood disorder, that are not classified as cancer, but may lead to severe diseases and therefore require treatment. These blood disorders include severe aplastic anemia (SAA), thalassemia, immune (idiopathic) thrombocytopenic purpura, congenital neutropenia, hemophilia, sickle-cell disease, iron deficiency anemia and various other diseases. In the past, due to the lack of effective treatments, many diseases have been called "incurable diseases". In recent years, with in-depth development of medical research, the treatment of blood diseases has been significantly improved. Modern medicine uses hormones, chemotherapy and other methods for the treatment of blood diseases, but the side effects are large, and the patient has a low cure rate and is prone to recurrence. Bone marrow transplantation for the treatment of leukemia was introduced then the cure rate of leukemia was improved. However, the bone marrow resources were very scarce, and a large part of the donated bone marrow was inconsistent with the patient's HLA, even if the transplant was successful, and the recurrence rate was as high as 70% within 5 years. Therefore, it is necessary to develop new therapies and drugs for the treatment of hematologic diseases. Hematonosis Compound Library from SAB provides you with compounds related to hematologic diseases that can be used for high throughput and high content screening.